Le Lézard
Classified in: Health, Science and technology, Business
Subject: FNC

AgaMatrix Announces Reorganization, and Formation of WaveForm Technologies Inc.



SALEM, N.H. and WILSONVILLE, Ore., Oct. 5, 2017 /PRNewswire/ -- AgaMatrix, Inc. today announced that it had concluded additional steps of a corporate reorganization, as approved by its shareholders and commenced in December 2016, to separate its business into two operating entities. The announced financing transaction with Prospect Capital Corporation (NASDAQ: PSEC) ("Prospect") concluded a significant step of the reorganization.

Upon the reorganization, a new holding company, AgaMatrix Holdings, LLC, was formed. AgaMatrix Holdings, LLC owns 100% of the capital stock of two operating businesses, AgaMatrix, Inc. ("AgaMatrix"), and WaveForm Technologies Inc. ("WaveForm"). The completed financing with Prospect enables AgaMatrix Holdings, LLC to facilitate capital plans for and investment in both businesses.

"With the completion of the Prospect transaction, we've initiated the remaining steps to complete the reorganization of our Company," said John Alberico, President and CEO of AgaMatrix Holdings LLC. "These next steps will enable each organization to focus on its strongest competencies and set an appropriate strategic direction. We are excited about the technology, products and services our two companies offer to the diabetes community and their caregivers."

AgaMatrix will continue to focus on its currently marketed blood glucose monitoring ("BGM") products and related technologies. AgaMatrix will manufacture and provide those products on a direct basis, as well as to the Company's major commercial partners. AgaMatrix products and technology include the recently launched Jazz Wireless 2 Bluetooth-enabled BGM product, the AgaMatrix Diabetes Manager software application, and an open source software development kit and HIPAA compliant cloud storage platform designed to facilitate easy and rapid development of Jazz Wireless 2 companion applications. AgaMatrix BGM products incorporate the Company's proprietary WaveSensetm technology. AgaMatrix BGM products have been shown in a number of independently conducted clinical studies to consistently provide more accurate measurements of blood glucose as compared to competing BGM platforms.

WaveForm Technologies to Develop and Commercialize Proprietary Continuous Glucose Monitoring and ?Closed Loop? Insulin Delivery Solutions

WaveForm Technologies will focus on the development of a proprietary continuous glucose monitoring ("CGM") platform, and related product opportunities. WaveForm's CGM technology was acquired in early 2016 from iSense CGM Inc. and Bayer Healthcare. The WaveForm CGM technology includes some of the earliest inventions and intellectual property relating to the continuous measurement of blood glucose, and offers several potential advantages as compared to currently marketed CGMs, including lower cost, longer potential sensor life and easy and painless needle insertion.

Prior to the acquisition, eight human clinical studies had been completed by Bayer Healthcare illustrating the technology's significant potential. WaveForm is currently conducting a series of additional human clinical trials designed to secure approval to market its CGM product candidate. WaveForm's clinical trials to date suggest its CGM technology provides measurements of blood glucose that are consistent with the accuracy and performance of currently marketed CGM products. WaveForm currently expects to receive CE mark approval for its CGM product candidate in the European Union in 2018, and is planning human clinical trials to support a PMA submission to seek approval to market and sell the system in the United States, potentially as early as 2019.

About AgaMatrix Holdings LLC, AgaMatrix Inc. and WaveForm Technologies, Inc.

AgaMatrix Holdings LLC is a holding company for two businesses that develop novel and proprietary technologies for diabetes care, AgaMatrix Inc. and WaveForm Technologies Inc.

AgaMatrix Inc. provides diagnostic technologies for diabetes care, including blood glucose monitoring devices and related firmware, software and data storage solutions. AgaMatrix has developed, manufactured and commercially launched 17 blood glucose monitoring products since the Company's 2001 inception, and has sold over 2 million blood glucose monitors and over 7 billion disposable test strips. AgaMatrix Inc. owns and operates manufacturing and engineering facilities in Salem, NH USA and in Guangdong Province, China.

WaveForm Technologies Inc. discovers and develops novel and proprietary new technologies for diabetes care. WaveForm's products under development include innovative continuous glucose monitoring technology, which is currently undergoing human clinical trials, and related firmware, software and data storage platforms. WaveForm is also developing a proprietary "closed loop" insulin delivery platform designed to provide a complete solution for patients living with diabetes.

Forward-Looking Statements and Historical Financial References

This press release contains forward-looking statements, which provide our current expectations or forecasts of future events. Forward-looking statements include, without limitation:

In some cases, you can identify forward-looking statements by words such as "anticipate," "believe" or "intend," but the absence of those words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons.

You should not unduly rely on these forward-looking statements, which speak only as of the date of this press release. We undertake no obligation to publicly update any forward-looking statements to reflect circumstances or events after the date of this press release, or to reflect the occurrence of unanticipated events.

For Additional Information
Cara Mottolo, AgaMatrix Holdings LLC 
Thomas Bailey, AgaMatrix Holdings LLC 
(603) 328?6000
investors@agamatrix.com

AgaMatrix, Inc. | 2017 (PRNewsfoto/AgaMatrix)

SOURCE AgaMatrix, Inc.


These press releases may also interest you

at 20:01
NEW YORK, Oct. 18, 2017 /PRNewswire/ -- MongoDB, Inc., the database for giant ideas, today announced the pricing of its initial public offering of 8,000,000 shares of its Class A common stock at a price to the public of $24.00 per share. The shares...

at 20:01
DENVER, Oct. 18, 2017 /PRNewswire/ -- MassRoots, Inc. (OTCQB:MSRT), one of the leading technology platforms for the cannabis industry, will hold a shareholder conference call hosted by the management team and Isaac Dietrich to discuss the Company's...

at 19:13
TAMPA, Fla., Oct. 18, 2017 /PRNewswire-USNewswire/ -- The Food and Drug Administration announced today the approval of Yescartatm (Axicabtagene ciloleucel), a revolutionary new immunotherapy for adult patients with diffuse large B cell lymphoma, a...

at 19:01
LONDON, October 19, 2017 /PRNewswire/ -- Customers can use the same data plan while travelling in 40 countries Truphone, the London-based global mobile tech disruptor, today announces it is offering data plans for iPad users with Apple SIM in...

at 19:01
LONDON, October 19, 2017 /PRNewswire/ -- London is Europe's leading fintech hub, according to recent investment data from London & Partners. Global investors continue to pump large sums of money into London fintech companies with the research...

at 18:45
DUBLIN, Oct. 18, 2017 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global biopharmaceutical company, today issued an FAQ document responding to investor questions following the U.S. District Court for the Eastern District of Texas trial...




News published on 5 october 2017 at 13:03 and distributed by: